MA31799B1 - Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p) - Google Patents

Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)

Info

Publication number
MA31799B1
MA31799B1 MA32805A MA32805A MA31799B1 MA 31799 B1 MA31799 B1 MA 31799B1 MA 32805 A MA32805 A MA 32805A MA 32805 A MA32805 A MA 32805A MA 31799 B1 MA31799 B1 MA 31799B1
Authority
MA
Morocco
Prior art keywords
modulators
compositions
sphingosin
phosphate receptor
sphingosine
Prior art date
Application number
MA32805A
Other languages
Arabic (ar)
English (en)
Inventor
Colleen Ruegger
Michael AMBÜHL
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31799(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31799B1 publication Critical patent/MA31799B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)

Abstract

L'invention concerne des compositions stables comprenant un modulateur du récepteur de sphingosine 1-phosphate (s1p), convenant pour une utilisation en tant que forme de dosage. Les modulateurs du récepteur s1p sont de manière typique des analogues de sphingosine, comme des dérivés de 2-amino-propane-1,3-diol ou de 2-aminopropanol substitué en position 2, par exemple un composé comprenant un groupe de la formule.
MA32805A 2007-10-12 2010-04-30 Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p) MA31799B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
PCT/US2008/079264 WO2009048993A2 (fr) 2007-10-12 2008-10-09 Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)

Publications (1)

Publication Number Publication Date
MA31799B1 true MA31799B1 (fr) 2010-10-01

Family

ID=40032615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32805A MA31799B1 (fr) 2007-10-12 2010-04-30 Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)

Country Status (33)

Country Link
US (6) US8673918B2 (fr)
EP (7) EP2465492B1 (fr)
JP (2) JP6034000B2 (fr)
KR (3) KR101600098B1 (fr)
CN (1) CN101820916A (fr)
AR (1) AR068986A1 (fr)
AU (1) AU2008310846C1 (fr)
BR (1) BRPI0818161B8 (fr)
CA (2) CA2925175A1 (fr)
CL (1) CL2008003003A1 (fr)
CO (1) CO6270342A2 (fr)
DK (1) DK2952177T3 (fr)
EC (1) ECSP10010169A (fr)
ES (2) ES2864671T3 (fr)
HK (1) HK1213768A1 (fr)
HR (1) HRP20150838T1 (fr)
HU (2) HUE027696T2 (fr)
IL (3) IL204514B (fr)
JO (2) JOP20080436B1 (fr)
MA (1) MA31799B1 (fr)
MX (1) MX337152B (fr)
MY (1) MY159358A (fr)
NZ (1) NZ600355A (fr)
PE (2) PE20130309A1 (fr)
PL (2) PL2952177T3 (fr)
PT (2) PT2465492E (fr)
RU (1) RU2010118457A (fr)
SG (2) SG187458A1 (fr)
SI (2) SI2465492T1 (fr)
TN (1) TN2010000136A1 (fr)
TW (1) TW200927142A (fr)
WO (1) WO2009048993A2 (fr)
ZA (1) ZA201001819B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
SG193803A1 (en) * 2008-08-18 2013-10-30 Novartis Ag Compounds for the treatment of peripheral neuropathies
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
ES2538413T3 (es) 2008-12-22 2015-06-19 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
WO2011131369A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod sous la forme de solution solide
WO2011131370A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod granulé fondu
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) * 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
SG10201602279PA (en) * 2011-10-21 2016-04-28 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (fr) 2011-12-22 2013-06-27 Synthon Bv Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (fr) * 2013-03-11 2014-09-18 Astron Research Limited Composition pharmaceutique stable de fingolimod
EP2996681B1 (fr) * 2013-05-13 2019-12-18 Synthon B.V. Composition pharmaceutique contenant du fingolimod
WO2015015254A1 (fr) 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Compositions pharmaceutiques à base de fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015155711A1 (fr) * 2014-04-10 2015-10-15 Novartis Ag Formulation d'immunosuppresseur
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (fr) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
CN113559075A (zh) * 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (fr) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Forme galénique solide stable de fingolimod
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
CN107530342A (zh) * 2015-04-28 2018-01-02 安斯泰来制药有限公司 口服给药用医药组合物
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
MX2018004021A (es) * 2015-10-02 2018-09-11 Mylan Inc Formulaciones estables de fingolimod.
SG11201809299QA (en) * 2016-04-22 2018-11-29 Incyte Corp Formulations of an lsd1 inhibitor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3419607B1 (fr) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Formulations stables de fingolimod
EP3813789A1 (fr) 2018-06-28 2021-05-05 Arx, LLC Procédé de distribution pour produire des constructions de film de dose unitaire soluble
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
KR20220142376A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406B1 (fr) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
CZ285953B6 (cs) 1995-12-28 1999-12-15 Yoshitomi Pharmaceutical Industries, Ltd. Vnější přípravek pro topické podání
EP2030614A1 (fr) 1997-02-27 2009-03-04 Novartis AG Composition pharmaceutique comprenant le 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol et une lécithine
KR100551931B1 (ko) 1997-04-04 2006-02-16 미츠비시 웰파마 가부시키가이샤 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1431284B1 (fr) 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
ATE463478T1 (de) 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
WO2003062248A2 (fr) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylates, phosphinates, phosphonates et tetrazoles en tant qu'agonistes de recepteur edg
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
AU2003264430B2 (en) 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
DE122011100047I1 (de) * 2003-04-08 2011-12-15 Mitsubishi Tanabe Pharma Corp Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
WO2005002559A2 (fr) 2003-06-24 2005-01-13 University Of Connecticut Procedes pour inhiber la permeabilite vasculaire et l'apoptose
AU2004268052B2 (en) 2003-08-28 2009-11-19 Novartis Ag Aminopropanol derivatives
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (fr) 2004-05-05 2005-12-01 Adler, Richard, S. Systemes et techniques de protection d'un bateau contre des attaques en surface ou sous l'eau
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006102611A2 (fr) 2005-03-24 2006-09-28 The Ohio State University Research Foundation Agents therapeutiques pour le traitement de la leucemie
CN1891212B (zh) 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
EP3103448B1 (fr) * 2006-09-26 2019-07-03 Novartis Ag Composes pharmaceutiques comprenant un modulateur s1p

Also Published As

Publication number Publication date
AU2008310846A1 (en) 2009-04-16
PL2952177T3 (pl) 2021-07-19
US20150165046A1 (en) 2015-06-18
JP6034000B2 (ja) 2016-11-30
TW200927142A (en) 2009-07-01
EP2465492B1 (fr) 2015-07-01
EP2653154A1 (fr) 2013-10-23
EP2209493A2 (fr) 2010-07-28
AU2008310846C1 (en) 2022-10-06
JP2011500583A (ja) 2011-01-06
KR101600098B1 (ko) 2016-03-04
US20100267675A1 (en) 2010-10-21
CN101820916A (zh) 2010-09-01
EP3733161A1 (fr) 2020-11-04
HRP20150838T1 (hr) 2015-11-06
PE20090799A1 (es) 2009-07-20
PE20130309A1 (es) 2013-03-30
IL277999A (en) 2020-11-30
EP2465492A1 (fr) 2012-06-20
SI2465492T1 (sl) 2015-12-31
IL255737A (en) 2018-01-31
KR20100091179A (ko) 2010-08-18
MX337152B (es) 2016-02-15
EP3733162A1 (fr) 2020-11-04
PL2465492T3 (pl) 2015-11-30
PT2952177T (pt) 2021-04-26
SG187458A1 (en) 2013-02-28
MY159358A (en) 2016-12-30
AR068986A1 (es) 2009-12-23
JOP20080436B1 (ar) 2023-03-28
JOP20210187A1 (ar) 2023-01-30
CO6270342A2 (es) 2011-04-20
IL255737B (en) 2020-10-29
TN2010000136A1 (en) 2011-09-26
US9399066B2 (en) 2016-07-26
ECSP10010169A (es) 2010-06-29
RU2010118457A (ru) 2011-11-20
KR20160025633A (ko) 2016-03-08
ZA201001819B (en) 2010-12-29
US20160296481A1 (en) 2016-10-13
SG10201800085XA (en) 2018-02-27
CA2925175A1 (fr) 2009-04-16
HUE027696T2 (en) 2016-10-28
DK2952177T3 (da) 2021-04-26
KR101710845B1 (ko) 2017-02-27
RU2016138157A3 (fr) 2020-02-10
MX2010003925A (es) 2010-05-05
EP3120833A1 (fr) 2017-01-25
US20140142192A1 (en) 2014-05-22
ES2545361T3 (es) 2015-09-10
AU2008310846B2 (en) 2012-06-21
JP2015091822A (ja) 2015-05-14
SI2952177T1 (sl) 2021-07-30
KR20170021904A (ko) 2017-02-28
WO2009048993A3 (fr) 2010-05-06
CA2699788C (fr) 2016-06-14
NZ600355A (en) 2013-02-22
WO2009048993A2 (fr) 2009-04-16
CA2699788A1 (fr) 2009-04-16
HUE053835T2 (hu) 2021-07-28
BRPI0818161A2 (pt) 2017-05-16
IL204514B (en) 2018-01-31
US20170151195A1 (en) 2017-06-01
EP2952177A1 (fr) 2015-12-09
US8673918B2 (en) 2014-03-18
ES2864671T3 (es) 2021-10-14
HK1213768A1 (zh) 2016-07-15
BRPI0818161B8 (pt) 2021-05-25
BRPI0818161B1 (pt) 2020-12-22
RU2016138157A (ru) 2018-12-13
CL2008003003A1 (es) 2009-05-15
PT2465492E (pt) 2015-10-15
EP2952177B1 (fr) 2021-01-20
US20170368001A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
MA31799B1 (fr) Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)
BRPI0612926B8 (pt) compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
EA200870079A1 (ru) Замещенные имидазолы и их применение в качестве пестицидов
ECSP088854A (es) Moduladores bencimidazolicos de vr1
MX2022008950A (es) Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
WO2008064320A3 (fr) Analogues d'hydrindane ayant une activité agoniste de récepteur de sphingosine-1-phosphate
TN2014000243A1 (fr) Benzopyrannes nouveaux, compositions les contenant et leurs utilisations
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
DOP2010000229A (es) Compuestos que comprenden un grupo ciclobutoxi
NO20074710L (no) 1H-Imidazolderivater som cannabinoid-CB2-receptormodulatorer
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
BRPI0510221A (pt) composto de aril cetona, composição, forma de dosagem unitária, uso da composição e método para preparar uma composição
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
SV2010003737A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
BR112012027385A2 (pt) composição para o controle de doenças de plantas e uso da mesma
HK1154777A1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
BRPI0900983A2 (pt) compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
WO2008152011A9 (fr) Catalyseur pour le durcissement d'époxydes
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
BRPI0504780A (pt) compostos de benzotiadiazina, processo para sua preparação e composições farmacêuticas contendo os mesmos